These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2447409)
1. Effects of long-term therapy with oral piroximone on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure. Nemanich JW; Shurman AJ; Rossen JD; Kremser C; Davis F; Rajfer SI J Cardiovasc Pharmacol; 1987 Nov; 10(5):580-8. PubMed ID: 2447409 [TBL] [Abstract][Full Text] [Related]
2. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. Petein M; Levine TB; Cohn JN Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778 [TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. Petein M; Levine TB; Cohn JN J Am Coll Cardiol; 1984 Aug; 4(2):364-71. PubMed ID: 6736478 [TBL] [Abstract][Full Text] [Related]
4. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. Weber KT; Janicki JS; Jain MC Am Heart J; 1987 Oct; 114(4 Pt 1):805-13. PubMed ID: 3310566 [TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. Axelrod RJ; De Marco T; Dae M; Botvinick EH; Chatterjee K J Am Coll Cardiol; 1987 May; 9(5):1124-30. PubMed ID: 3571752 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with piroximone in patients with chronic heart failure. Baumann G; Ningel K; Cremer G Int J Cardiol; 1990 Nov; 29(2):195-204. PubMed ID: 2269538 [TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of a constant intravenous infusion of piroximone in patients with severe congestive heart failure. Miller WE; Kennedy GT; Ruberg SJ; O'Rourke RA; Crawford MH J Cardiovasc Pharmacol; 1988 Jul; 12(1):72-7. PubMed ID: 2459538 [TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. Baumann PC; Meyer BJ; Maggiorini M; Ha HR; Gallino A; Follath F J Cardiovasc Pharmacol; 1993 Mar; 21(3):489-95. PubMed ID: 7681513 [TBL] [Abstract][Full Text] [Related]
9. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Uretsky BF; Valdes AM; Reddy PS Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328 [TBL] [Abstract][Full Text] [Related]
10. Acute hemodynamic effects of piroximone (MDL 19,205) in patients with moderate congestive heart failure: comparison with sodium nitroprusside. Arbogast R; Brandt CM; Fincker JL; Schechter PJ J Cardiovasc Pharmacol; 1986; 8(1):82-9. PubMed ID: 2419699 [TBL] [Abstract][Full Text] [Related]
11. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672 [TBL] [Abstract][Full Text] [Related]